Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
Immunity ; 53(6): 1258-1271.e5, 2020 12 15.
Artigo em Inglês | MEDLINE | ID: mdl-33296686

RESUMO

CD4+ T cells reactive against SARS-CoV-2 can be found in unexposed individuals, and these are suggested to arise in response to common cold coronavirus (CCCoV) infection. Here, we utilized SARS-CoV-2-reactive CD4+ T cell enrichment to examine the antigen avidity and clonality of these cells, as well as the relative contribution of CCCoV cross-reactivity. SARS-CoV-2-reactive CD4+ memory T cells were present in virtually all unexposed individuals examined, displaying low functional avidity and multiple, highly variable cross-reactivities that were not restricted to CCCoVs. SARS-CoV-2-reactive CD4+ T cells from COVID-19 patients lacked cross-reactivity to CCCoVs, irrespective of strong memory T cell responses against CCCoV in all donors analyzed. In severe but not mild COVID-19, SARS-CoV-2-specific T cells displayed low functional avidity and clonality, despite increased frequencies. Our findings identify low-avidity CD4+ T cell responses as a hallmark of severe COVID-19 and argue against a protective role for CCCoV-reactive T cells in SARS-CoV-2 infection.


Assuntos
Linfócitos T CD4-Positivos/imunologia , COVID-19/imunologia , Receptores de Antígenos de Linfócitos T/metabolismo , Rhinovirus/imunologia , SARS-CoV-2/imunologia , Antígenos Virais/imunologia , Células Cultivadas , Reações Cruzadas , Progressão da Doença , Exposição Ambiental , Humanos , Memória Imunológica , Ativação Linfocitária , Ligação Proteica , Índice de Gravidade de Doença , Especificidade do Receptor de Antígeno de Linfócitos T
2.
BMC Anesthesiol ; 22(1): 385, 2022 Dec 12.
Artigo em Inglês | MEDLINE | ID: mdl-36503438

RESUMO

BACKGROUND: Primary viral myocarditis associated with severe acute respiratory syndrome coronavirus 2 (SARS-Cov2) infection is a rare diagnosis. CASE PRESENTATION: We report the case of an unvaccinated, healthy patient with cardiogenic shock in the context of a COVID-19-associated myocarditis and therapy with simultaneous veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and percutaneous left ventricular decompression therapy with an Impella. The aim of this review is to provide an overview of therapeutic options for patients with COVID-19-associated myocarditis. CONCLUSIONS: The majority of patients required a combination of two assist devices to achieve sufficient cardiac output until recovery of left ventricular ejection fraction. Due to the rapid onset of this fulminant cardiogenic shock immediate invasive bridging therapy in a specialized center was lifesaving.


Assuntos
COVID-19 , Coração Auxiliar , Miocardite , Humanos , Choque Cardiogênico/etiologia , Choque Cardiogênico/terapia , Volume Sistólico , RNA Viral , Função Ventricular Esquerda , COVID-19/complicações , COVID-19/terapia , SARS-CoV-2 , Miocardite/complicações , Miocardite/terapia , Miocardite/diagnóstico
3.
Anesthesiology ; 134(3): 457-467, 2021 03 01.
Artigo em Inglês | MEDLINE | ID: mdl-33417674

RESUMO

BACKGROUND: The hemostatic balance in patients with coronavirus disease 2019 (COVID-19) seems to be shifted toward a hypercoagulable state. The aim of the current study was to assess the associated coagulation alterations by point-of-care-diagnostics, focusing on details of clot formation and lysis in these severely affected patients. METHODS: The authors' prospective monocentric observational study included critically ill patients diagnosed with COVID-19. Demographics and biochemical data were recorded. To assess the comprehensive hemostatic profile of this patient population, aggregometric (Multiplate) and viscoelastometric (CloPro) measures were performed in the intensive care unit of a university hospital at a single occasion. Coagulation analysis and assessment of coagulation factors were performed. Data were compared to healthy controls. RESULTS: In total, 27 patients (21 male; mean age, 60 yr) were included. Impedance aggregometry displayed no greater platelet aggregability in COVID-19 in comparison with healthy controls (area under the curve [AUC] in adenosine diphosphate test, 68 ± 37 U vs. 91 ± 29 U [-27 (Hodges-Lehmann 95% CI, -48 to -1); P = 0.043]; AUC in arachidonic acid test, 102 ± 54 U vs. 115 ± 26 U [-21 (Hodges-Lehmann 95% CI, -51 to 21); P = 0.374]; AUC in thrombin receptor activating peptide 6 test, 114 ± 61 U vs. 144 ± 31 U [-31 (Hodges-Lehmann 95% CI, -69 to -7); P = 0.113]). Comparing the thromboelastometric results of COVID-19 patients to healthy controls, the authors observed significant differences in maximum clot firmness in fibrin contribution to maximum clot firmness assay (37 ± 11 mm vs. 15 ± 4 mm [21 (Hodges-Lehmann 95% CI, 17 to 26); P < 0.001]) and lysis time in extrinsic activation and activation of fibrinolysis by tissue plasminogen activator assay (530 ± 327 s vs. 211 ± 80 s [238 (Hodges-Lehmann 95% CI, 160 to 326); P < 0.001]). CONCLUSIONS: Thromboelastometry in COVID-19 patients revealed greater fibrinolysis resistance. The authors did not find a greater platelet aggregability based on impedance aggregometric tests. These findings may contribute to our understanding of the hypercoagulable state of critically ill patients with COVID-19.


Assuntos
COVID-19 , Fibrinólise , Estado Terminal , Humanos , Masculino , Pessoa de Meia-Idade , Agregação Plaquetária , Estudos Prospectivos , SARS-CoV-2 , Tromboelastografia , Ativador de Plasminogênio Tecidual
6.
Med Klin Intensivmed Notfmed ; 119(3): 181-188, 2024 Apr.
Artigo em Alemão | MEDLINE | ID: mdl-38108880

RESUMO

BACKGROUND: Natural language processing (NLP) has experienced significant growth in recent years and shows potential for broad impacts in scientific research and clinical practice. OBJECTIVE: This study comprises an exploration of the role of NLP in scientific research and its subsequent effects on traditional publication practices, as well as an evaluation of the opportunities and challenges offered by large language models (LLM) and a reflection on necessary paradigm shifts in research culture. MATERIALS AND METHODS: Current LLMs, such as ChatGPT, and their potential applications were compared and assessed. An analysis of the literature and case studies on the integration of LLMs into scientific and clinical practice was conducted. RESULTS AND CONCLUSION: LLMs provide enhanced access to and processing capabilities of text-based information and represent a vast potential for (medical) research as well as daily clinical practice. Chat-based LLMs enable efficient completion of often time-consuming tasks, but due to their tendency for hallucinations, have a significant limitation. Current developments require critical examination and a paradigm shift to fully exploit the benefits of LLMs and minimize potential risks.


Assuntos
Processamento de Linguagem Natural
7.
Med Klin Intensivmed Notfmed ; 118(5): 366-371, 2023 Jun.
Artigo em Alemão | MEDLINE | ID: mdl-37115245

RESUMO

BACKGROUND: With the free provision of the chat robot "ChatGPT" by the company OpenAI in November 2022, an application of artificial intelligence (AI) became tangible for everyone. OBJECTIVES: An explanation of the basic functionality of large language models (LLM) is given, followed by a presentation of application options of ChatGPT in medicine, and an outlook and discussion of possible dangers of AI applications. METHODS: Problem solving with ChatGPT using concrete examples. Analysis and discussion of the available scientific literature. RESULTS: There has been a significant increase in the use of AI applications in scientific work, especially in scientific writing. Wide application of LLM in writing medical documentation is conceivable. Technical functionality allows the use of AI applications as a diagnostic support system. There is a risk of spreading and entrenching inaccuracies and bias through application of LLM. Regulation of this new technology is pending. CONCLUSION: AI applications such as ChatGPT have the potential to permanently change everyday medical practice. An examination of this technology and evaluation of opportunities and risks is warranted.


Assuntos
Inteligência Artificial , Medicina , Humanos , Documentação
8.
Shock ; 58(6): 514-523, 2022 12 01.
Artigo em Inglês | MEDLINE | ID: mdl-36548643

RESUMO

ABSTRACT: Background: Severe progression of coronavirus disease 2019 (COVID-19) causes respiratory failure and critical illness. Recently, COVID-19 has been associated with heparanase (HPSE)-induced endothelial barrier dysfunction and inflammation, so called endothelitis, and therapeutic treatment with heparin or low-molecular-weight heparin (LMWH) targeting HPSE has been postulated. Because, up to this date, clinicians are unable to measure the severity of endothelitis, which can lead to multiorgan failure and concomitant death, we investigated plasma levels of HPSE and heparin-binding protein (HBP) in COVID-19 intensive care patients to render a possible link between endothelitis and these plasma parameters. Therefore, a prospective prolonged cohort study was conducted, including 47 COVID-19 patients from the intensive care unit. Plasma levels of HPSE, and HBP were measured daily by enzyme-linked immunosorbent assay in survivors (n = 35) and nonsurvivors (n = 12) of COVID-19 from admission until discharge or death. All patients were either treated with heparin or LMWH, aiming for an activated partial thromboplastin time of ≥60 seconds or an anti-Xa level of >0.8 IU/mL using enoxaparin, depending on the clinical status of the patient (patients with extracorporeal membrane oxygenation or >0.1 µg/kg/min noradrenaline received heparin, all others enoxaparin). Results: We found significantly higher plasma levels of HPSE and HBP in survivors and nonsurvivors of COVID-19, compared with healthy controls. Still, interestingly, plasma HPSE levels were significantly higher ( P < 0.001) in survivors compared with nonsurvivors of COVID-19. In contrast, plasma HBP levels were significantly reduced ( P < 0.001) in survivors compared with nonsurvivors of COVID-19. Furthermore, when patients received heparin, they had significantly lower HPSE ( P = 2.22 e - 16) and significantly higher HBP ( P = 0.00013) plasma levels as when they received LMWH. Conclusion: Our results demonstrated that patients, who recover from COVID-19-induced vascular and pulmonary damage and were discharged from the intensive care unit, have significantly higher plasma HPSE level than patients who succumb to COVID-19. Therefore, HPSE is not suitable as marker for disease severity in COVID-19 but maybe as marker for patient's recovery. In addition, patients receiving therapeutic heparin treatment displayed significantly lower heparanse plasma level than upon therapeutic treatment with LMWH.


Assuntos
COVID-19 , Endotélio Vascular , Glucuronidase , Pulmão , Doenças Vasculares , Humanos , Estudos de Coortes , COVID-19/sangue , COVID-19/complicações , COVID-19/diagnóstico , Enoxaparina , Heparina/uso terapêutico , Heparina de Baixo Peso Molecular/uso terapêutico , Estudos Prospectivos , Sobreviventes , Glucuronidase/sangue , Recuperação de Função Fisiológica , Endotélio Vascular/fisiopatologia , Endotélio Vascular/virologia , Doenças Vasculares/diagnóstico , Doenças Vasculares/virologia , Pulmão/fisiopatologia , Pulmão/virologia , Tratamento Farmacológico da COVID-19
9.
J Clin Virol ; 146: 105052, 2022 01.
Artigo em Inglês | MEDLINE | ID: mdl-34920374

RESUMO

BACKGROUND: Antibody detection of SARS-CoV-2 requires an understanding of its variation, course, and duration. METHODS: Antibody response to SARS-CoV-2 was evaluated over 5-430 days on 828 samples across COVID-19 severity levels, for total antibody (TAb), IgG, IgA, IgM, neutralizing antibody (NAb), antibody avidity, and for receptor-binding-domain (RBD), spike (S), or nucleoprotein (N). Specificity was determined on 676 pre-pandemic samples. RESULTS: Sensitivity at 30-60 days post symptom onset (pso) for TAb-S/RBD, TAb-N, IgG-S, IgG-N, IgA-S, IgM-RBD, and NAb was 96.6%, 99.5%, 89.7%, 94.3%, 80.9%, 76.9% and 92.8%, respectively. Follow-up 430 days pso revealed: TAb-S/RBD increased slightly (100.0%); TAb-N decreased slightly (97.1%); IgG-S and IgA-S decreased moderately (81.4%, 65.7%); NAb remained positive (94.3%), slightly decreasing in activity after 300 days; there was correlation with IgG-S (Rs = 0.88) and IgA-S (Rs = 0.71); IgG-N decreased significantly from day 120 (15.7%); IgM-RBD dropped after 30-60 days (22.9%). High antibody avidity developed against S/RBD steadily with time in 94.3% of patients after 430 days. This correlated with persistent antibody detection depending on antibody-binding efficiency of the test design. Severe COVID-19 correlated with earlier and higher antibody response, mild COVID-19 was heterogeneous with a wide range of antibody reactivities. Specificity of the tests was ≥99%, except for IgA (96%). CONCLUSION: Sensitivity of anti-SARS-CoV-2 assays was determined by test design, target antigen, antibody avidity, and COVID-19 severity. Sustained antibody detection was mainly determined by avidity progression for RBD and S. Testing by TAb and for S/RBD provided the highest sensitivity and longest detection duration of 14 months so far.


Assuntos
COVID-19 , SARS-CoV-2 , Anticorpos Neutralizantes , Anticorpos Antivirais , Formação de Anticorpos , Humanos , Imunoglobulina G , Imunoglobulina M , Cinética , Glicoproteína da Espícula de Coronavírus
10.
Front Med (Lausanne) ; 7: 599533, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33392222

RESUMO

Background: Proportions of patients dying from the coronavirus disease-19 (COVID-19) vary between different countries. We report the characteristics; clinical course and outcome of patients requiring intensive care due to COVID-19 induced acute respiratory distress syndrome (ARDS). Methods: This is a retrospective, observational multicentre study in five German secondary or tertiary care hospitals. All patients consecutively admitted to the intensive care unit (ICU) in any of the participating hospitals between March 12 and May 4, 2020 with a COVID-19 induced ARDS were included. Results: A total of 106 ICU patients were treated for COVID-19 induced ARDS, whereas severe ARDS was present in the majority of cases. Survival of ICU treatment was 65.0%. Median duration of ICU treatment was 11 days; median duration of mechanical ventilation was 9 days. The majority of ICU treated patients (75.5%) did not receive any antiviral or anti-inflammatory therapies. Venovenous (vv) ECMO was utilized in 16.3%. ICU triage with population-level decision making was not necessary at any time. Univariate analysis associated older age, diabetes mellitus or a higher SOFA score on admission with non-survival during ICU stay. Conclusions: A high level of care adhering to standard ARDS treatments lead to a good outcome in critically ill COVID-19 patients.

11.
J Gynecol Obstet Hum Reprod ; 48(4): 269-273, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-30685429

RESUMO

BACKGROUND: Postpartum hemorrhage is the leading cause of maternal death. Recently, the WOMAN trial showed that early administration of tranexamic acid leads to a reduced mortality due to bleeding. The aim was to study whether the results of the WOMAN trial have influenced the institutional standard operating procedures in treating postpartum hemorrhage. METHODS: We performed a paper-based survey during the German Perinatal Congress in 2017 located in Berlin. A total of thirteen questions covered the fields of incidence, training, and treatment of postpartum hemorrhage. RESULTS: 250 questionnaires were handed out to all participants of three different sessions during the congress. 72 questionnaires were returned, resulting in a return rate of 29%. 94% (n = 65) of all participants stated that they had implemented a standard operating procedure to treat postpartum hemorrhage prior to the WOMAN trial. 18 of these standard operating procedures were revised after the publication of the WOMAN trial, resulting in an early inclusion of tranexamic acid in 100% of all standard operating procedures. CONCLUSION: We recognized a correlation between the publication of the WOMAN trial and the administration of tranexamic acid at an early time-point in all standard operating procedures of the participating institutions to treat postpartum hemorrhage. In all those clinics whose algorithms initially did not contain any tranexamic acid, it was supplemented. This resulted in a 100% implementation of tranexamic acid.


Assuntos
Antifibrinolíticos/uso terapêutico , Obstetrícia/normas , Hemorragia Pós-Parto/tratamento farmacológico , Ácido Tranexâmico/administração & dosagem , Algoritmos , Berlim , Coeficiente de Natalidade , Ensaios Clínicos como Assunto , Feminino , Humanos , Obstetrícia/métodos , Obstetrícia/tendências , Padrões de Prática Médica/estatística & dados numéricos , Gravidez , Inquéritos e Questionários , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA